Last reviewed · How we verify
Atorvastatin and fenofibrate
This combination reduces blood lipids by inhibiting cholesterol synthesis (atorvastatin) and activating peroxisome proliferator-activated receptors to increase triglyceride clearance (fenofibrate).
This combination reduces blood lipids by inhibiting cholesterol synthesis (atorvastatin) and activating peroxisome proliferator-activated receptors to increase triglyceride clearance (fenofibrate). Used for Dyslipidemia with elevated LDL cholesterol and triglycerides, Cardiovascular risk reduction in patients with mixed hyperlipidemia.
At a glance
| Generic name | Atorvastatin and fenofibrate |
|---|---|
| Also known as | Lipitor, Lofibra |
| Sponsor | The University of Western Australia |
| Drug class | Statin and fibrate combination |
| Target | HMG-CoA reductase and PPAR-α |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Atorvastatin is an HMG-CoA reductase inhibitor that blocks cholesterol production in the liver, lowering LDL cholesterol. Fenofibrate is a fibric acid derivative that activates PPAR-α, increasing lipoprotein lipase activity and reducing triglycerides while raising HDL cholesterol. Together, they provide complementary lipid-lowering effects targeting multiple dyslipidemia pathways.
Approved indications
- Dyslipidemia with elevated LDL cholesterol and triglycerides
- Cardiovascular risk reduction in patients with mixed hyperlipidemia
Common side effects
- Myalgia or muscle pain
- Elevated liver enzymes
- Gastrointestinal upset
- Headache
- Rhabdomyolysis (rare)
Key clinical trials
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (PHASE3)
- Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (PHASE3)
- Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (PHASE3)
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin (PHASE3)
- Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP. (PHASE3)
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atorvastatin and fenofibrate CI brief — competitive landscape report
- Atorvastatin and fenofibrate updates RSS · CI watch RSS
- The University of Western Australia portfolio CI